Search for: "Serono, Inc."
Results 1 - 20
of 25
Sort by Relevance
|
Sort by Date
19 Apr 2022, 5:05 am
The Anti-Kickback Statute prohibits offering or accepting kickbacks intended to generate health care business. [read post]
20 Sep 2021, 3:31 pm
EMD Serono, Inc., the Federal Circuit found the claimed treatment method anticipated by use of a naturally occurring protein. [read post]
28 Jun 2021, 2:04 pm
EMD Serono, Inc. [read post]
3 May 2021, 4:15 am
EMD Serono, Inc., 976 F.3d 1326 (Fed. [read post]
3 May 2021, 4:15 am
EMD Serono, Inc., 976 F.3d 1326 (Fed. [read post]
6 Oct 2020, 7:55 am
EMD Serono, Inc., and includes an interesting discussion of claim construction for method claims reciting product-by-process limitations. [read post]
30 Sep 2020, 6:33 am
EMD Serono, Inc., reversing the U.S. [read post]
30 Sep 2020, 6:33 am
EMD Serono, Inc., reversing the U.S. [read post]
30 Sep 2020, 5:47 am
On September 28, 2020, in Biogen Ma Inc. v. [read post]
29 Sep 2020, 9:50 pm
EMD Serono, Inc. [read post]
28 Sep 2020, 8:00 am
EMD Serono, Inc. [read post]
7 Feb 2019, 12:08 pm
EMD Serono, Inc., both in the Eastern District of Pennsylvania; United States ex rel. [read post]
1 Apr 2016, 3:02 am
EMD Serono, Inc., 2016 WL 1086028 (N.D. [read post]
31 Mar 2016, 3:00 am
EMD Serono, Inc., No. 5:14-cv-01709-MHH, 2016 WL 1086028 (Mar. 21, N.D. [read post]
13 Jun 2012, 6:22 pm
Mark Halligan, Partner, Nixon Peabody LLP and Thomas Kelley, Consulting Patent Counsel, Monsanto Company Speaker: Jason Duncan, Associate General Counsel, EMD, Serono, Inc. [read post]
7 Feb 2012, 2:25 pm
Circuit precedent, Judge Jackson noted that the Court’s observations in Serono Labs., Inc. v. [read post]
18 May 2011, 4:46 am
Pharmaceutical manufacturers Serono Laboratories, Inc., EMD Serono, Inc., Merck Serono S.A., and Ares Trading S.A., have agreed to pay $44.3 million to resolve False Claims Act allegations in connection with the marketing of the drug Rebif. [read post]
5 May 2011, 2:57 pm
Pharmaceutical giants: Serono Laboratories Inc., EMD Serono Inc., Merck Serono S.A, and Ares Trading S.A. have agreed to settle False Claims Act allegations in connection with the marketing of the drug Rebif for $44.3 million, according to a recent announcement by the Department of Justice. [read post]
4 May 2011, 6:14 am
According to DOJ’s press release: P harmaceutical manufacturers Serono Laboratories Inc., EMD Serono Inc., Merck Serono S.A, and Ares Trading S.A. have agreed to pay $44.3 million to resolve False Claims Act allegations in connection with the marketing of the drug Rebif, the Justice Department announced. [read post]
10 Jun 2010, 3:58 am
EMD Serono, Inc. et al. [read post]
